Australian (ASX) Stock Market Forum

IMU - Imugene Limited

Jump to new
Reverse trend affect happening with IMU does it have the fundamentals to hold up and bounce. Buy now all the stayers will be selling, not along term investment, pitty had a lot of respect for this trade. think it would go a long way. Perhaps not a lot of production going on, it really needs to sell it achievements. Put another pair of bails on the stumps. its not bowled out yet...Down 25% LBW...
 
Last edited:
Put another pair of bails on the stumps. its not bowled out yet...Down 25% LBW...Down another 13% today...bowled middle stump (yorker)
1623124997569.png
 
IMU bounces back today up nearly 10% back of Investers Presentation maybe. The Sellers have stop selling and the buys are back in...

Imugene Limited (ASX: IMU), would like to clarify the Investor Webinar Presentation announcement released earlier today on 11 June 2021, titled ‘Investor Webinar Presentation’. Please note the correct date and time for the ShareCafe Small Cap "Hidden Gems" Webinar to be held today, is Friday, 11th June 2021 from 12:30pm AEST / 10:30am AWST.

1623394764980.png
 
Is really a hidden gem...Little bird' y tells me to expect stronger gains from IMU next wk interesting to see how it pans out...
 

Attachments

  • 1624595667827.png
    1624595667827.png
    36 KB · Views: 15
Trying to get back in to the good books is Imugene who had this to say;

Investment View: Upgrade to Buy (Spec), Valuation raised

The key changes to earnings include the 6% dilution to shares on issue from the recent $90m capital raise. The company now has c. $130m in cash. We have increased the clinical trial spend in the period FY22 – FY25 and now expect IMU will spend at least $30m annually on development. The long dated years of the DCF have been amended to include potential future revenues from the onCARlytics program, now expected to commence clinical trials in FY23. Valuation is raised to $0.52 from $0.25 and we upgrade to Buy (Spec). The potential of these new therapies may be attractive to future development partners.

I am personally very excited about the transformational opportunities we are developing. I encourage you to continue to follow our progress.
 
Stockybailz said:
Trying to get back in to the good books is Imugene who had this to say;

Investment View: Upgrade to Buy (Spec), Valuation raised

The key changes to earnings include the 6% dilution to shares on issue from the recent $90m capital raise. The company now has c. $130m in cash. We have increased the clinical trial spend in the period FY22 – FY25 and now expect IMU will spend at least $30m annually on development. The long dated years of the DCF have been amended to include potential future revenues from the onCARlytics program, now expected to commence clinical trials in FY23. Valuation is raised to $0.52 from $0.25 and we upgrade to Buy (Spec). The potential of these new therapies may be attractive to future development partners.

I am personally very excited about the transformational opportunities we are developing. I encourage you to continue to follow our progress.
Click to expand...
At the outset a long time holder of IMU but now got nervous:
  1. A director Dr. Leslie Russell a world-class pharma expert who only joined in 2019 https://www.proactiveinvestors.com....aceutical-executive-to-its-board-218913.html; https://static1.squarespace.com/sta...1559573706876/IMU_FA_Newsletter_Jun19_web.pdf) sold out some 30 pc of her holding in a systematic way :https://www.asx.com.au/asxpdf/20211011/pdf/451j82dcg75mv6.pdf
  2. prices are going south in a systematic way
  3. Investor presentation was apparently good https://cdn-api.markitdigital.com/a...access_token=83ff96335c2d45a094df02a206a39ff4
1633951579088.png

  1. 1633951104452.png
 
Miner said:
At the outset a long time holder of IMU but now got nervous:
  1. A director Dr. Leslie Russell a world-class pharma expert who only joined in 2019 https://www.proactiveinvestors.com....aceutical-executive-to-its-board-218913.html; https://static1.squarespace.com/sta...1559573706876/IMU_FA_Newsletter_Jun19_web.pdf) sold out some 30 pc of her holding in a systematic way :https://www.asx.com.au/asxpdf/20211011/pdf/451j82dcg75mv6.pdf
  2. prices are going south in a systematic way
  3. Investor presentation was apparently good https://cdn-api.markitdigital.com/a...access_token=83ff96335c2d45a094df02a206a39ff4
View attachment 131411
  1. View attachment 131409
Click to expand...
IMU has gone south again this morning.
What is getting cooked in the kitchen and who is cooking ?
Is the smell coming of a curry or Nippon
1633994611058.png
 
If @Miner still holding - IMU chart is suggestive of a significant low made off 21c.
Last three weekly candles: indecisive doji, hammer reversal, decent sized white.
Been superficially looking at two other Paul Hopper associated companies which might have got to buyable levels although their charts are not yet showing reversals: RAD and CHM.

Weekly
big - 2022-03-20T151409.270.gif
 
My pick this month for the stock tipping comp. IMU has been on a long term down trend and seems to have bottomed. So hopefully we will see a good rise on April.

Iggy
 
IMU quarterly looking positive, but the recent correction pushed the price down a bit. Hoping we will get a bounce during May. From the other aspect of IMU, the company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors , which is a great cause for humanity, and would be great to see some positive outcomes.

Iggy
 
15th March 2022 - Marriage was registered :
Share price was 0.265 at the time of closing .Market Value was approximately $19,370,523

2nd May 2022- Divorce was declared

Share price went down by 13.64 % and closed at 19.5 cents; Market value $14,253,781
Immediate cost of divorce per market value of shares was $5,116,742 .
38 days loss converted to annual loss 254% :(:mad:

 
finicky said:
If @Miner still holding - IMU chart is suggestive of a significant low made off 21c.
Last three weekly candles: indecisive doji, hammer reversal, decent sized white.
Been superficially looking at two other Paul Hopper associated companies which might have got to buyable levels although their charts are not yet showing reversals: RAD and CHM.

WeeklyView attachment 139261
Click to expand...
@finicky - sorry to miss your query . I have sold off IMU about two months back.
 
Iggy_Pop said:
IMU quarterly looking positive, but the recent correction pushed the price down a bit. Hoping we will get a bounce during May. From the other aspect of IMU, the company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors , which is a great cause for humanity, and would be great to see some positive outcomes.

Iggy
Click to expand...
@Iggy_Pop I am sure no one was expecting the bouncer in May to strike off the wickets in one stroke.
IMU gave me fantastic gains but with constant down ward movement with no news, I regrettably deserted my old friend couple of months back.
Being technically strong business case otherwise, I am looking for a re-entry after doing some impact assessment of the termination of the agreement with MSD.
 
IMU has been dragged down by the general negative trend with biotech companies, but is financially ok, with a number of trials progressing. Will bounce up and hold at some point. Was up 12% one day in May, before dropping again. Great for traders

Iggy
 
Imugene is providing fresh hope for gastric cancer patients thanks to the development of an oncolytic virus that infects and breaks down cancer cells, but not normal cells.

In combination with chemotherapy, the results showed gastric cancer patients had a median overall survival of 13.9 months, compared to those treated with just chemotherapy, who lived for 8.3 months.

The study also showed there was no difference in safety events between the two treatment groups, suggesting that HER-Vaxx does not add any toxicity to chemotherapy.

........ up 45% today, 17c to 24c, but was above 60c last November.
 
This is a pick in the Monthly comp. from left field for me.

Two of the top people are coming to Aust from America for a seminar presentation in early Nov. and a Fox interview to follow.

General thought is that for this to happen there should be some good news to go with it.

The Fox interview is thought to be for informing USA market.
 
Trials and research into various forms of cancer cure/treatment have continued to successfully progress during the past year.

Share price has plummeted over this period however, starting with a big international conference this month, they are going global on what they have achieved and the big pharmacutical company products they are already working with to improve efficiencies.

I do not consider them an immediate take-over target due to the diversity of their trials, but big pharmas will, possibly this year, be wanting joint agreements with up-front payments to IMU.
 

Imugene (ASX:IMU) receives US patent for PD1-Vaxx​

themarketherald.com.au

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

Immuno-oncology specialist Imugene (ASX:IMU) has been granted a patent in the United States for its lung cancer treatment product, PD1-Vaxx.
themarketherald.com.au themarketherald.com.au

PD1-Vaxx is a B-cell activating immunotherapy for non-small cell lung cancer (NSCLC). Imugene said it had final preparations in place for a PD1-Vaxx clinical trial in the US and Australia

Live price charts: https://uk.advfn.com/p.php?pid=staticchart&s=ASX^IMU&p=0&t=1
 

Similar threads

T
MXD - Matrix Gold
Replies
0
Views
5K
Trader Paul
T
T
GGX - Gas2GridLimited
2
Replies
30
Views
8K
barney
barney
Y
MYG - Mutiny Gold
2
Replies
23
Views
11K
System
System
Y
POW - Protean Energy
2 3
Replies
41
Views
13K
greggles
greggles
Y
TEX - Target Energy
2 3
Replies
59
Views
16K
Sim81
S
Top